🇺🇸 FDA
Pipeline program

A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment

S095031-218

Phase 1 other active

Quick answer

A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment for Newly diagnosed and/or previously treated IDH1-mutated malignancies is a Phase 1 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Newly diagnosed and/or previously treated IDH1-mutated malignancies
Phase
Phase 1
Modality
other
Status
active

Clinical trials